Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment
Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment
About this item
Full title
Author / Creator
Publisher
Waltham, MA: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Waltham, MA: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
A man with undiagnosed chronic myelomonocytic leukemia began treatment with vemurafenib for BRAF-mutant metastatic melanoma. His white-cell count soared and then dropped when the drug was withdrawn. The leukemia cells contained an RAS mutation that became more active with RAF inhibition.
Approximately 50% of patients with metastatic melanoma har...
Alternative Titles
Full title
Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3627494
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3627494
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1208958
